Formulation development for hydrophobic therapeutic proteins
- PMID: 17613886
- DOI: 10.1080/10837450701247350
Formulation development for hydrophobic therapeutic proteins
Abstract
The major challenges in formulation development for hydrophobic proteins are low solubility often combined with a strong tendency for adsorption. Human serum albumin (HSA) is frequently used as excipient to overcome these problems. Due to several drawbacks with HSA, new ways need to be found to circumvent the use of this excipient in protein formulations. One possible approach is to select an appropriate formulation pH and ionic strength in combination with excipients that provide sufficient stability and solubility for the hydrophobic protein. A reduction in adsorption can be achieved by adding surfactants or using special containers.
Similar articles
-
Recent trends in stabilising peptides and proteins in pharmaceutical formulation - considerations in the choice of excipients.Expert Opin Drug Deliv. 2009 Nov;6(11):1219-30. doi: 10.1517/17425240903199143. Expert Opin Drug Deliv. 2009. PMID: 19678792 Review.
-
IgG1 adsorption to siliconized glass vials-influence of pH, ionic strength, and nonionic surfactants.J Pharm Sci. 2015 Jan;104(1):34-43. doi: 10.1002/jps.24239. Epub 2014 Nov 12. J Pharm Sci. 2015. PMID: 25394280
-
Stabilization of a hydrophobic recombinant cytokine by human serum albumin.J Pharm Sci. 2007 Nov;96(11):2987-99. doi: 10.1002/jps.20909. J Pharm Sci. 2007. PMID: 17786949
-
Bilateral Effects of Excipients on Protein Stability: Preferential Interaction Type of Excipient and Surface Aromatic Hydrophobicity of Protein.Pharm Res. 2017 Jul;34(7):1378-1390. doi: 10.1007/s11095-017-2152-0. Epub 2017 Apr 11. Pharm Res. 2017. PMID: 28401430
-
Microspheres and microcapsules for protein delivery: strategies of drug activity retention.Curr Pharm Des. 2013;19(35):6340-52. doi: 10.2174/1381612811319350010. Curr Pharm Des. 2013. PMID: 23470006 Review.
Cited by
-
Sensitivity of human pluripotent stem cells to insulin precipitation induced by peristaltic pump-based medium circulation: considerations on process development.Sci Rep. 2017 Jun 21;7(1):3950. doi: 10.1038/s41598-017-04158-x. Sci Rep. 2017. PMID: 28638147 Free PMC article.
-
Monoclonal antibody interactions with micro- and nanoparticles: adsorption, aggregation, and accelerated stress studies.J Pharm Sci. 2009 Sep;98(9):3218-38. doi: 10.1002/jps.21768. J Pharm Sci. 2009. PMID: 19492408 Free PMC article.
-
Regulatory Guidelines for the Analysis of Therapeutic Peptides and Proteins.J Pept Sci. 2025 Mar;31(3):e70001. doi: 10.1002/psc.70001. J Pept Sci. 2025. PMID: 39921384 Free PMC article. Review.
-
Glycosylation of therapeutic proteins: an effective strategy to optimize efficacy.BioDrugs. 2010 Feb 1;24(1):9-21. doi: 10.2165/11530550-000000000-00000. BioDrugs. 2010. PMID: 20055529 Free PMC article. Review.
-
Designing Formulation Strategies for Enhanced Stability of Therapeutic Peptides in Aqueous Solutions: A Review.Pharmaceutics. 2023 Mar 14;15(3):935. doi: 10.3390/pharmaceutics15030935. Pharmaceutics. 2023. PMID: 36986796 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources